MSTN and Duchenne muscular dystrophy: In the mdx mouse model of DMD, inhibition of myostatin with RK35, a murine antibody equivalent of domagrozumab, led to increased muscle mass and strength, with decreased fat substitution and fibrosis [6, 17, 31].